Transforming growth factor-beta1 suppresses hepatocellular carcinoma proliferation via activation of Hippo signaling
Metrics: PDF 1036 views | HTML 895 views | ?
Xiaodong Zhang1,*, Qing Fan1,*, Yan Li1,2,*, Zhaoguo Yang1, Liang Yang1, Zhihong Zong3, Biao Wang3, Xin Meng3, Qin Li1, Jingang Liu1 and Hangyu Li1
1Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P. R. China
2Department of Oncology, Tumour Angiogenesis and Microenvironment Laboratory (TAML), The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, P. R. China
3Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences of China Medical University, Shenyang, P. R. China
*These authors have contributed equally to this work
Hangyu Li, email: email@example.com
Keywords: transforming growth factor-beta, hepatocellular carcinoma, Hippo signaling, proliferation
Received: August 10, 2016 Accepted: December 27, 2016 Published: January 05, 2017
In this study, we examined the expression of core proteins of the Hippo signaling pathway in hepatocellular carcinoma (HCC) cells treated with transforming growth factor-β 1(TGF-β1) and investigated the relationship between TGF-β1 and the Hippo signaling pathway, in order to better understand their roles in HCC and their potential implications for cancer therapy. We prove that the Hippo signaling pathway is involved in the TGF-β1-induced inhibition of the growth of HCC cells. Large tumor suppressor expression (LATS1) was overexpression and yes association protein 1(YAP1) translocated from the nucleus to the cytoplasm in HCC cells treated with TGF-β1. Overexpression of LATS1 and the nucleocytoplasmic translocation of YAP1 play an anti-oncogenetic role in the occurrence and development of liver cancer. Our findings provide new insight into strategies for liver cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.